David Taylor
@vpresearchals.bsky.social
VP Research & Strategic Partnerships @ ALS Canada. Science brain, advocate heart.
There seems to be some chatter about Ellorarxine as a 'miracle drug' for ALS/MND right now. For perspective, there are many other drugs that currently have the same level or far more published evidence of potential value for ALS/MND. Often. We probably see a few per month like this. So let's see...
January 8, 2025 at 11:10 PM
There seems to be some chatter about Ellorarxine as a 'miracle drug' for ALS/MND right now. For perspective, there are many other drugs that currently have the same level or far more published evidence of potential value for ALS/MND. Often. We probably see a few per month like this. So let's see...
Reposted by David Taylor
It would be amazing if everyone connected to ALS reposted this. It says many of the things researchers have said behind the scenes for years, in publication form.
New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of 'clinical trends' and miscommunication. academic.oup.com/brain/articl...
Rethinking phase 2 trials in amyotrophic lateral sclerosis
There is a long history of ALS therapies being promoted on the basis of Phase 2 data, which then fail to translate into meaningful benefits in Phase 3 tria
academic.oup.com
December 11, 2024 at 5:19 PM
It would be amazing if everyone connected to ALS reposted this. It says many of the things researchers have said behind the scenes for years, in publication form.
Reposted by David Taylor
Reposted by David Taylor
Kaly Mueller, Senior Associate Scientist at ALS TDI, was awarded one of three Poster Prizes for her outstanding presentation at the 35th International Symposium on ALS/MND this past weekend.
December 10, 2024 at 4:25 PM
Kaly Mueller, Senior Associate Scientist at ALS TDI, was awarded one of three Poster Prizes for her outstanding presentation at the 35th International Symposium on ALS/MND this past weekend.
Reposted by David Taylor
Check out the ALS Trial Navigator – your comprehensive resource for making decisions about ALS clinical trials. Use our tools to understand your clinical trial options and have informed discussions with your care team. Learn more here: www.als.net/als-trial-navigator/
December 9, 2024 at 10:42 PM
Check out the ALS Trial Navigator – your comprehensive resource for making decisions about ALS clinical trials. Use our tools to understand your clinical trial options and have informed discussions with your care team. Learn more here: www.als.net/als-trial-navigator/
Reposted by David Taylor
The NeurdyPhagy Lab is in Montreal talking all about palmitoylation in ALS MND. Stop by our posters & say hi.
@jesuisyasmeena.bsky.social
@cailyncreative.bsky.social
@jesuisyasmeena.bsky.social
@cailyncreative.bsky.social
December 7, 2024 at 2:43 PM
The NeurdyPhagy Lab is in Montreal talking all about palmitoylation in ALS MND. Stop by our posters & say hi.
@jesuisyasmeena.bsky.social
@cailyncreative.bsky.social
@jesuisyasmeena.bsky.social
@cailyncreative.bsky.social
Reposted by David Taylor
We are excited to be here in Montreal for @mndassoc.bsky.social #alsmndsymp! We would be delighted to see you at our posters - see below for our presenters and poster numbers #MND #ALS
December 6, 2024 at 1:32 AM
We are excited to be here in Montreal for @mndassoc.bsky.social #alsmndsymp! We would be delighted to see you at our posters - see below for our presenters and poster numbers #MND #ALS
Reposted by David Taylor
We also have several group members giving platform talks as well as a plenary lecture! We would be delighted to see you there - see below for our presenters and talks #MND #ALS @mndassoc.bsky.social #alsmndsymp
December 6, 2024 at 1:34 AM
We also have several group members giving platform talks as well as a plenary lecture! We would be delighted to see you there - see below for our presenters and talks #MND #ALS @mndassoc.bsky.social #alsmndsymp
Important work Lizzie and great talk at the Symposium.
(1/3) Happy to share our new work assessing protein changes in CSF of 48 asymptomatic C9orf72 variant carriers at higher risk of #ALS and #FTD.
We find an elevation in levels of UCHL1 protein, even in the absence of elevation in #neurofilament (NFL).
onlinelibrary.wiley.com/doi/full/10....
We find an elevation in levels of UCHL1 protein, even in the absence of elevation in #neurofilament (NFL).
onlinelibrary.wiley.com/doi/full/10....
Elevated Cerebrospinal Fluid Ubiquitin Carboxyl‐Terminal Hydrolase Isozyme L1 in Asymptomatic C9orf72 Hexanucleotide Repeat Expansion Carriers
Objective To identify biochemical changes in individuals at higher risk of developing amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) via C9orf72 hexanucleotide repeat expansion...
onlinelibrary.wiley.com
December 9, 2024 at 7:24 PM
Important work Lizzie and great talk at the Symposium.
Reposted by David Taylor
The end of the 35th International Symposium on #ALS #MND in Montreal. A fantastic few days with the world's leading ALS researchers in the company of patient fellows. Thank you to the @mndassoc.bsky.social @alscanada.bsky.social Brian Dickie and the wonderful MNDA team for putting it all together.
December 8, 2024 at 9:25 PM
The end of the 35th International Symposium on #ALS #MND in Montreal. A fantastic few days with the world's leading ALS researchers in the company of patient fellows. Thank you to the @mndassoc.bsky.social @alscanada.bsky.social Brian Dickie and the wonderful MNDA team for putting it all together.
Reposted by David Taylor
A Patient Fellows scarf on @ammaralchalabi.bsky.social on the big stage.
December 6, 2024 at 1:35 PM
A Patient Fellows scarf on @ammaralchalabi.bsky.social on the big stage.
Oof. Can we get an AI based autocorrect program that changes “breakthrough” to “interesting” or “intriguing” already? This after touting efficacy signs from their open label trial earlier this year.
December 9, 2024 at 7:03 PM
Oof. Can we get an AI based autocorrect program that changes “breakthrough” to “interesting” or “intriguing” already? This after touting efficacy signs from their open label trial earlier this year.
I heard from many people that Healing ALS was at the Symposium. I didn’t cross paths but I feel like it would be great for someone to do a (very compassionately approached) study on the feelings of people whose loved one died after spending all their money and effort on the 47 Steps to Healing ALS.
December 9, 2024 at 4:02 PM
I heard from many people that Healing ALS was at the Symposium. I didn’t cross paths but I feel like it would be great for someone to do a (very compassionately approached) study on the feelings of people whose loved one died after spending all their money and effort on the 47 Steps to Healing ALS.
The talk on the negative C9ORF72 ASO trial sticks with me most. ASO got into neurons and stayed there, sense strand DPRs decreased in CSF, but they were still present in tissue! Do we need to try sense strand gain-of-function again? How do we trust CSF readings to reflect tissue moving forward? 🤕
December 9, 2024 at 4:11 AM
The talk on the negative C9ORF72 ASO trial sticks with me most. ASO got into neurons and stayed there, sense strand DPRs decreased in CSF, but they were still present in tissue! Do we need to try sense strand gain-of-function again? How do we trust CSF readings to reflect tissue moving forward? 🤕
This reminds me that someone should check-in on Tikomed and Helixmith about their HGF development. I suppose I could just Google them. HGF is not uninteresting based on preclinical data…
Lucky petrie dishes...
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing...
www.globenewswire.com
December 9, 2024 at 3:49 AM
This reminds me that someone should check-in on Tikomed and Helixmith about their HGF development. I suppose I could just Google them. HGF is not uninteresting based on preclinical data…
Reposted by David Taylor
Let’s move away from early dx term and call it what it should be — prompt dx. #alsmndsymp
December 7, 2024 at 1:58 PM
Let’s move away from early dx term and call it what it should be — prompt dx. #alsmndsymp
Just on a train home from seven full days of meetings in Montreal with 1000+ of my favourite global peeps and a whack-load of Canucks. So many people tackling big problems collaboratively. This is one of my takeaways of 2024 vs. years past. Progress can be hard to see but it’s definitely there.
December 9, 2024 at 3:39 AM
Just on a train home from seven full days of meetings in Montreal with 1000+ of my favourite global peeps and a whack-load of Canucks. So many people tackling big problems collaboratively. This is one of my takeaways of 2024 vs. years past. Progress can be hard to see but it’s definitely there.
But we are making progress and people are working hard, with urgency!
December 9, 2024 at 3:21 AM
But we are making progress and people are working hard, with urgency!
I could give many tips for reading press releases about ALS discoveries & treatments. For now, just remind yourself that the data & statistics you see are almost never the actual story. Breakthroughs usually aren’t breakthroughs & great trial results are usually polished up to look their very best.
December 9, 2024 at 3:19 AM
I could give many tips for reading press releases about ALS discoveries & treatments. For now, just remind yourself that the data & statistics you see are almost never the actual story. Breakthroughs usually aren’t breakthroughs & great trial results are usually polished up to look their very best.